"Re-re-treatment?" Third and fourth courses of BRAF/MEK inhibition in advanced melanoma

被引：0
作者：
O'Brien, Michael T. [1 ]
Iwamoto, Sage [2 ]
Haq, Rizwan [3 ]
Johnson, Douglas B. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Hematol Oncol, Nashville, TN USA
[2] Vanderbilt Univ, Sch Med, Nashville, TN USA
[3] Dana Farber Canc Inst, Dept Med, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2025年 / 220卷
关键词：
Melanoma; BRAF inhibitor; MEK inhibitor; Encorafenib; Binimetinib; Dabrafenib; Trametinib; Re-treatment; RESISTANCE;
D O I：
10.1016/j.ejca.2025.115378
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 6 条
  • [1] Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
    Albrecht, Lea Jessica
    Dimitriou, Florentia
    Grover, Piyush
    Hassel, Jessica C.
    Erdmann, Michael
    Forschner, Andrea
    Johnson, Douglas B.
    Varaljai, Renata
    Lodde, Georg
    Placke, Jan Malte
    Krefting, Frederik
    Zaremba, Anne
    Ugurel, Selma
    Roesch, Alexander
    Schulz, Carsten
    Berking, Carola
    Poettgen, Christoph
    Menzies, Alexander M.
    Long, Georgina V.
    Dummer, Reinhard
    Livingstone, Elisabeth
    Schadendorf, Dirk
    Zimmer, Lisa
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [2] BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma
    Cybulska-Stopa, Bozena
    Rogala, Pawel
    Czarnecka, Anna M.
    Galus, Lukasz
    Dziura, Robert
    Rajczykowski, Marcin
    Kubiatowski, Tomasz
    Wisniewska, Magdalena
    Gega-Czarnota, Adrianna
    Teterycz, Pawel
    Ziobro, Marek
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    [J]. MELANOMA RESEARCH, 2020, 30 (05) : 465 - 471
  • [3] Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
    Das Thakur, Meghna
    Salangsang, Fernando
    Landman, Allison S.
    Sellers, William R.
    Pryer, Nancy K.
    Levesque, Mitchell P.
    Dummer, Reinhard
    McMahon, Martin
    Stuart, Darrin D.
    [J]. NATURE, 2013, 494 (7436) : 251 - 255
  • [4] Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
    Moriceau, Gatien
    Hugo, Willy
    Hong, Aayoung
    Shi, Hubing
    Kong, Xiangju
    Yu, Clarissa C.
    Koya, Richard C.
    Samatar, Ahmed A.
    Khanlou, Negar
    Braun, Jonathan
    Ruchalski, Kathleen
    Seifert, Heike
    Larkin, James
    Dahlman, Kimberly B.
    Johnson, Douglas B.
    Algazi, Alain
    Sosman, Jeffrey A.
    Ribas, Antoni
    Lo, Roger S.
    [J]. CANCER CELL, 2015, 27 (02) : 240 - 256
  • [5] Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
    Valpione, Sara
    Carlino, Matteo S.
    Mangana, Johanna
    Mooradian, Meghan J.
    McArthur, Grant
    Schadendorf, Dirk
    Hauschild, Axel
    Menzies, Alexander M.
    Arance, Ana
    Ascierto, Paolo A.
    Di Giacomo, AnnaMaria
    de Rosa, Francesco
    Larkin, James
    Park, John J.
    Goldinger, Simone M.
    Sullivan, Ryan J.
    Xu, Wen
    Livingstone, Elisabeth
    Weichenthal, Michael
    Rai, Rajat
    Gaba, Lydia
    Long, Georgina V.
    Lorigan, Paul
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 91 : 116 - 124
  • [6] BRAF/MEK inhibitor rechallenge in advanced melanoma patients
    Van Not, Olivier J.
    van den Eertwegh, Alfons J. M.
    Haanen, John B.
    van Rijn, Rozemarijn S.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    Blank, Christian U.
    Boers-Sonderen, Marye J.
    de Groot, Jan Willem W. B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Bloem, Manja
    Piersma, Djura
    Stevense-den Boer, Marion
    Verheijden, Rik J.
    van der Veldt, Astrid A. M.
    Wouters, Michel W. J. M.
    Blokx, Willeke A. M.
    Suijkerbuijk, Karijn P. M.
    [J]. CANCER, 2024, 130 (09) : 1673 - 1683
1